Produktname:3-Chloro-5-(p-tolyl)-1,2,4-triazine
IUPAC Name:3-chloro-5-(4-methylphenyl)-1,2,4-triazine
- CAS：1368414-41-8
- Molekulare Formel：C10H8ClN3
- Reinheit：95%
- Katalognummer：CM121753
- Molekulargewicht：205.65
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:1368414-41-8
- Molekulare Formel:C10H8ClN3
- Schmelzpunkt:-
- SMILES-Code:CC1=CC=C(C2=CN=NC(Cl)=N2)C=C1
- Dichte:
- Katalognummer:CM121753
- Molekulargewicht:205.65
- Siedepunkt:
- Mdl-Nr.:MFCD21962268
- Lagerung:
Category Infos
- Triazines
- Triazines are an important class of six-membered aromatic heterocycles with three nitrogen atoms that give rise to three regioisomers: 1,2,4-triazines, 1,2,3-triazines, and 1,3, 5-triazine. 1,2,3-Triazines show remarkable reactivity and have attracted attention for their medicinal value. Triazine compounds fused with other carbon and heterocycles are stable and have a broad spectrum of pharmacological activities.
Column Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
- Lorundrostat
- Mineralys Therapeutics announced that the first subject has been dosed in the Launch-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment. Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled and resistant hypertension and CKD. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Suche 
+86 21 5895 0110 
